Candriam S.C.A. Sorrento Therapeutics, Inc. Call Options Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SRNE
# of Institutions
12Shares Held
5.47MCall Options Held
0Put Options Held
0-
B. Riley Securities, Inc. Los Angeles, CA5.22MShares$1.72 Million1.01% of portfolio
-
Swisspartners Ltd. Vaduz, N2110KShares$36,3000.12% of portfolio
-
Lattice Capital Management, LLC51.8KShares$17,0940.02% of portfolio
-
High Point Advisor Group LLC Downers Grove, IL22.3KShares$7,3420.0% of portfolio
-
Slate Stone Wealth, LLC21.4KShares$7,0720.0% of portfolio
About Sorrento Therapeutics, Inc.
- Ticker SRNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 449,952,000
- Market Cap $148M
- Description
- Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...